This will help advance the field of organoid-based cancer models." The review on tissue dissociation techniques is poised to make a significant impact on oncology research, especially for solid ...

The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...

The research topic on “manipulation of immune‒vascular crosstalk in solid tumors” will focus on understanding how tumor blood vessels govern ... You will choose your team of co-editors, curate a list ...

However, CAR-T cell application in solid tumors remains challenging. There is an unmet clinical need for better cellular therapies for solid tumors. The team of researchers, led by Xiaowei ...

BGB-43395 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) ...

Disitamab vedotin is under clinical development by Pfizer and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo ...